The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The growing prevalence of hypertension, depression, diabetes and heart disorders has increased the risk of OSA among individuals, thereby representing one of the key drivers for the global positive airway pressure devices market.
Sudden outbreak of the COVID-19 pandemic has led to expanding applications of PAP devices to treat type 1 respiratory failure in patients diagnosed with the coronavirus infection, thereby positively influencing the market growth.
Several key players are introducing compact and convenient product variants with improved noise reduction features which represents one of the key trends in the global positive airway pressure devices market.
On the basis of the product type, the market has been bifurcated into automatic positive airway pressure (APAP) devices, continuous positive airway pressure (CPAP) devices, and bi-level positive airway pressure (BiPAP) devices. Currently, continuous positive airway pressure (CPAP) devices hold the majority of the total market share.
On the basis of the end-user, the market has been segmented into hospitals and sleep labs, home care, and others. At present, hospitals and sleep labs exhibit a clear dominance in the market.
Region-wise, the market has been classified into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America, where North America dominates the global market.
The key companies in the global positive airway pressure devices market are 3B Medical Inc., Apex Medical Corp., Compumedics Limited (D & DJ Burton Holdings Pty Ltd.), Drive Devilbiss Healthcare (Drive International LLC), Fisher & Paykel Healthcare Limited, Koninklijke Philips N.V., Resmed Inc., Smiths Group Plc, Somnetics International Inc., and Vyaire Medical Inc.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at